2-Year Outcomes of High Bleeding Risk Patients with Acute Coronary Syndrome After Biolimus-A9 Polymer-Free Drug-Coated Stents: a Leaders Free Sub-study

EuroIntervention

1 February Feb 2018 6 months ago
  • Fabbiocchi F

The Leaders Free ACS sub-study demonstrated that a Biolimus-A9 drug coated stent (DCS) is more effective and safer than a bare metal stent (BMS) at 12 months follow up in high-bleeding risk (HBR) patients with acute coronary syndrome (ACS). This analysis extends the follow-up to 2 years.

Reference
Jensen CJ, Naber CK, Urban P, Ong PJ, Valdes-Chavarri M, Abizaid AA, Pocock SJ, Fabbiocchi F, Dubois C, Copt S, Stoll HP, Morice MC. 2-Year Outcomes of High Bleeding Risk Patients with Acute Coronary Syndrome After Biolimus-A9 Polymer-Free Drug-Coated Stents: a Leaders Free Sub-study. EuroIntervention 2018 Jan 16. pii: EIJ-D-17-00720. doi: 10.4244/EIJ-D-17-00720. [Epub ahead of print]

Go to PubMed